Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 8/20 | 0.49 |
| ▸ | CA1 | P00915 | 5/20 | 0.45 |
| ▸ | CA2 | P00918 | 5/20 | 0.45 |
| ▸ | CA12 | O43570 | 3/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15255352 | 0.96 | MEN1 (0.55) | MEN1KMT2AGAATDP1CA1 | |
| SCHEMBL2742774 | 0.86 | KMT2A (0.49) | MEN1KMT2AGAATDP1CA1 | |
| SCHEMBL13464451 | 0.86 | KMT2A (0.49) | MEN1KMT2AGAATDP1CA1 | |
| Hydrochloric Acid SCHEMBL28852622 | 0.85 | KMT2A (0.48) | MEN1KMT2AGAATDP1CA1 | |
| SCHEMBL14871948 | 0.84 | MEN1 (0.59) | MEN1KMT2AGAATDP1CA1 | |
| SCHEMBL11916883 | 0.83 | MEN1 (0.55) | MEN1KMT2AGAATDP1CA1 | |
| SCHEMBL19864338 | 0.83 | MEN1 (0.58) | MEN1KMT2AGAATDP1CA1 | |
| SCHEMBL14930702 | 0.82 | KDM4E (0.44) | TDP1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL1276827 | 0.82 | TDP1 (0.54) | MEN1KMT2AGAATDP1CA1 | |
| SCHEMBL11916880 | 0.81 | MEN1 (0.52) | MEN1KMT2AGAATDP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642344-B2 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20080009613-A1 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-7247434-B2 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES, INC. (US) | 2007-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009613-A1 | Methods and compositions for determining the sequence of nucleic acid molecules | CPSF6, RNMT, POLM | MEN1 3916/4885KMT2A 1215/4885GAA 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.